Categorization of 77 dystrophin exons into 5 groups by a decision tree using indexes of splicing regulatory factors as decision markers

BMC Genetics

Masafumi Matsuo¹  Yasuhiro Takeshima³  Atsushi Nishida⁴  Ery Kus Dwianingsih³  Tomoko Lee³  Hiroyuki Awano³  Mariko Yagi³  Yutaka Takaoka²  Rusdy Ghazali Malueka³ 

[1] Department of Medical Rehabilitation, Faculty of Rehabilitation, Kobegakuin University, 518 Arise, Ikawadani, Nishi, Kobe 651-2180, Japan;Division of Medical Informatics and Bioinformatics, Kobe University Hospital, Chuo, Kobe 6500017, Japan;Department of Pediatrics, Graduate School of Medicine, Kobe University, Chuo, Kobe 6500017, Japan;Department of Clinical Pharmacy, Kobe Pharmaceutical University, Higashinada, Kobe 6588558, Japan

关键词: Decision tree;    Splicing enhancer;    Exon;    Dystrophin;    Splicing;   

Others  :  1122491
DOI  :  10.1186/1471-2156-13-23

 received in 2012-01-18, accepted in 2012-03-31,  发布年份 2012

【 摘 要 】

Background

Duchenne muscular dystrophy, a fatal muscle-wasting disease, is characterized by dystrophin deficiency caused by mutations in the dystrophin gene. Skipping of a target dystrophin exon during splicing with antisense oligonucleotides is attracting much attention as the most plausible way to express dystrophin in DMD. Antisense oligonucleotides have been designed against splicing regulatory sequences such as splicing enhancer sequences of target exons. Recently, we reported that a chemical kinase inhibitor specifically enhances the skipping of mutated dystrophin exon 31, indicating the existence of exon-specific splicing regulatory systems. However, the basis for such individual regulatory systems is largely unknown. Here, we categorized the dystrophin exons in terms of their splicing regulatory factors.

Results

Using a computer-based machine learning system, we first constructed a decision tree separating 77 authentic from 14 known cryptic exons using 25 indexes of splicing regulatory factors as decision markers. We evaluated the classification accuracy of a novel cryptic exon (exon 11a) identified in this study. However, the tree mislabeled exon 11a as a true exon. Therefore, we re-constructed the decision tree to separate all 15 cryptic exons. The revised decision tree categorized the 77 authentic exons into five groups. Furthermore, all nine disease-associated novel exons were successfully categorized as exons, validating the decision tree. One group, consisting of 30 exons, was characterized by a high density of exonic splicing enhancer sequences. This suggests that AOs targeting splicing enhancer sequences would efficiently induce skipping of exons belonging to this group.

Conclusions

The decision tree categorized the 77 authentic exons into five groups. Our classification may help to establish the strategy for exon skipping therapy for Duchenne muscular dystrophy.

【 授权许可】

   
2012 Malueka et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M: Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 1995, 95:515-520.
• [2]Aartsma-Rus A: Antisense-mediated modulation of splicing: Therapeutic implications for duchenne muscular dystrophy. RNA Biol 2010, 7(4):453-461.
• [3]Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T: The Status of Exon Skipping as a Therapeutic Approach to Duchenne Muscular Dystrophy. Mol Ther 2011, 19:9-15.
• [4]Ahn AH, Kunkel LM: The structural and functional diversity of dystrophin. Nat Genet 1993, 3:283-291.
• [5]Nishio H, Takeshima Y, Narita N, Yanagawa H, Suzuki Y, Ishikawa Y, Minami R, Nakamura H, Matsuo M: Identification of a novel first exon in the human dystrophin gene and of a new promoter located more than 500 kb upstream of the nearest known promoter. J Clin Invest 1994, 94:1037-1042.
• [6]Feener CA, Koenig M, Kunkel LM: Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 1989, 338:509-511.
• [7]Sironi M, Cagliani R, Pozzoli U, Bardoni A, Comi GP, Giorda R, Bresolin N: The dystrophin gene is alternatively spliced throughout its coding sequence. FEBS Lett 2002, 517:163-166.
• [8]Kubokawa I, Takeshima Y, Ota M, Enomoto M, Okizuka Y, Mori T, Nishimura N, Awano H, Yagi M, Matsuo M: Molecular characterization of the 5'-UTR of retinal dystrophin reveals a cryptic intron that regulates translational activity. Mol Vis 2010, 16:2590-2597.
• [9]Sun H, Chasin LA: Multiple splicing defects in an intronic false exon. Mol Cell Biol 2000, 20:6414-6425.
• [10]Zhang Z, Habara Y, Nishiyama A, Oyazato Y, Yagi M, Takeshima Y, Matsuo M: Identification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons. J Hum Genet 2007, 52:607-617.
• [11]Valadkhan S: Role of the snRNAs in spliceosomal active site. RNA Biol 2010, 7:345-353.
• [12]Matlin AJ, Clark F, Smith CW: Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005, 6:386-398.
• [13]Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H, Ota M, Itoh K, Hagiwara M, Matsuo M: Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2011, 2:308.
• [14]Kingsford C, Salzberg SL: What are decision trees? Nat Biotechnol 2008, 26:1011-1013.
• [15]Allen JE, Majoros WH, Pertea M, Salzberg SL: JIGSAW, GeneZilla, and GlimmerHMM: puzzling out the features of human genes in the ENCODE regions. Genome Biol 2006, 7(Suppl 1:S9):1-13.
• [16]Nishiyama A, Takeshima Y, Zhang Z, Habara Y, Tran TH, Yagi M, Matsuo M: Dystrophin nonsense mutations can generate alternative rescue transcripts in lymphocytes. Ann Hum Genet 2008, 72:717-724.
• [17]Královicová J, Vorechovsky I: Global control of aberrant splice-site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition. Nucleic Acids Res 2007, 35:6399-6413.
• [18]David MP, Concepcion GP, Padlan EA: Using simple artificial intelligence methods for predicting amyloidogenesis in antibodies. BMC Bioinforma 2010, 11:79. BioMed Central Full Text
• [19]Shiga N, Takeshima Y, Sakamoto H, Inoue K, Yokota Y, Yokoyama M, Matsuo M: Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest 1997, 100:2204-2210.
• [20]Buratti E, Chivers M, Královicová J, Romano M, Baralle M, Krainer A, Vorechovsky I: Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 2007, 35:4250-4263.
• [21]Dhir A, Buratti E: Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies. FEBS J 2010, 277:841-855.
• [22]Vorechovsky I: Transposable elements in disease-associated cryptic exons. Hum Genet 2010, 127:135-154.
• [23]Dhir A, Buratti E, van Santen MA, Luhrmann R, Baralle FE: The intronic splicing code: multiple factors involved in ATM pseudoexon definition. EMBO J 2010, 29:749-760.
• [24]Wei B, Jin JP: Troponin T isoforms and posttranscriptional modifications: Evolution, regulation and function. Arch Biochem Biophys 2011, 505:144-154.
• [25]Matsuo M, Masumura T, Nishio H, Nakajima T, Kitoh Y, Takumi T, Koga J, Nakamura H: Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy Kobe. J Clin Invest 1991, 87:2127-2131.
• [26]Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M: Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996, 226:445-449.
• [27]Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M: Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 2006, 59:690-694.
• [28]Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, Nishio H, Matsuo M: Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet 2010, 55:379-388.
• [29]Yagi M, Takeshima Y, Wada H, Nakamura H, Matsuo M: Two alternative exons can result from activation of the cryptic splice acceptor site deep within intron 2 of the dystrophin gene in a patient with as yet asymptomatic dystrophinopathy. Hum Genet 2003, 112:164-170.
• [30]Beroud C, Carrie A, Beldjord C, Deburgrave N, Llense S, Carelle N, Peccate C, Cuisset JM, Pandit F, Carre-Pigeon F, et al.: Dystrophinopathy caused by mid-intronic substitutions activating cryptic exons in the DMD gene. Neuromuscul Disord 2004, 14:10-18.
• [31]Shapiro MB, Senapathy P: RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987, 15:7155-7174.
• [32]Yeo G, Burge CB: Maximum entrophy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 2003, 11:377-394.
• [33]Nalla VK, Rogan PK: Automated splicing mutation analysis by information theory. Hum Mutat 2005, 25:334-342.
• [34]Ast G: How did alternative splicing evolve? Nat Rev Genet 2004, 5:773-782.
• [35]Schwartz S, Hall E, Ast G: SROOGLE: webserver for integrative, user-friendly visualization of splicing signals. Nucleic Acids Res 2009, 37(Web Server):W189-192.
• [36]Fairbrother WG, Yeh RF, Sharp PA, Burge CB: Predictive identification of exonic splicing enhancers in human genes. Science 2002, 297:1007-1013.
• [37]Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB: Systematic identification and analysis of exonic splicing silencers. Cell 2004, 119:831-845.
• [38]Zhang XH, Chasin LA: Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 2004, 18:1241-1250.
• [39]Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003, 31:3568-3571.
• [40]Zhang J, Kuo CC, Chen L: GC content around splice sites affects splicing through pre-mRNA secondary structures. BMC Genomics 2011, 12:90. BioMed Central Full Text
• [41]Gruber AR, Lorenz R, Bernhart SH, Neubock R, Hofacker IL: The Vienna RNA websuite. Nucleic Acids Res 2008, 36(Web Server):W70-74.
• [42]Han J, Kamber M, Pei J: Data Mining: Concepts and Techniques. Waltham, Massachusetts: Morgan Kaufmann Publishers; 2011.
• [43]Witten IH, Frank E: Practical Machine Learning Tools and Techniques. Waltham, Massachusetts: Morgan Kaufmann Publishers; 2005.
• [44]Quinlan JR: C4.5: Programs for Machine Learning. Waltham, Massachusetts: Morgan Kaufmann Publishers; 1993.
• [45]Quinlan JR: Improved Use of Continuous Attributes in C. J Artif Intell Res 1996, 4:77-90.
• [46]Surono A, Takeshima Y, Wibawa T, Ikezawa M, Nonaka I, Matsuo M: Circular dystrophin RNAs consisting of exons that were skipped by alternative splicing. Hum Mol Genet 1999, 8:493-500.